Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

C.M. Wheeler, X. Castellsagué, S.M. Garland, A. Szarewski, J. Paavonen, P. Naud, J. Salmerón, S.-N. Chow, D. Apter, H. Kitchener, J.C. Teixeira, Susan Skinner, U. Jaisamrarn, G. Limson, B. Romanowski, F.Y. Aoki, T.F. Schwarz, W.A.J. Poppe, F.X. Bosch, D.M. HarperW. Huh, K. Hardt, T. Zahaf, D. Descamps, F. Struyf, G. Dubin, M. Lehtinen

    Research output: Contribution to journalArticle

    362 Citations (Scopus)
    Original languageEnglish
    Pages (from-to)100-110
    JournalThe Lancet Oncology
    Issue number1
    Publication statusPublished - 2012

    Cite this